In the BioHarmony Drug Report Database

"Preview" Icon

Casimersen

Amondys (casimersen) is an oligonucleotide pharmaceutical. Casimersen was first approved as Amondys on 2021-02-25. It is used to treat duchenne muscular dystrophy in the USA. Amondys 45’s patents are valid until 2030-11-12 (FDA).

 

Trade Name

 

Amondys
 

Common Name

 

casimersen
 

ChEMBL ID

 

CHEMBL4297566
 

Indication

 

duchenne muscular dystrophy
 

Drug Class

 

Antisense oligonucleotides

Image (chem structure or protein)

Casimersen structure rendering